Stock Markets February 20, 2026

Society Pass Shares Drop After Regulatory Update on NusaTrip Trading Halt

Majority-owned NusaTrip remains under regulatory review as its Nasdaq securities stay suspended; Society Pass stock reacts with a double-digit decline

By Hana Yamamoto SOPA NUTR
Society Pass Shares Drop After Regulatory Update on NusaTrip Trading Halt
SOPA NUTR

Shares of Society Pass Incorporated (NASDAQ:SOPA) fell 12.5% following a regulatory update from its majority-owned unit, NusaTrip Incorporated (NASDAQ:NUTR). NusaTrip disclosed a sequence of responses to Nasdaq and SEC information requests and confirmed that trading in its securities on Nasdaq remains halted while it continues to cooperate with regulators. The company said daily operations have not been materially affected by the suspension.

Key Points

  • Society Pass shares fell 12.5% after NusaTrip provided a regulatory update.
  • NusaTrip disclosed a series of responses to Nasdaq and SEC information requests; its Nasdaq trading remains halted.
  • NusaTrip reports daily operations are unchanged; companies involved operate in Southeast Asia e-commerce and travel technology sectors.

Society Pass Incorporated saw its stock price decline 12.5% on Friday after its majority-owned subsidiary, NusaTrip Incorporated, released an update about regulatory inquiries tied to the trading status of NusaTrip securities on The Nasdaq Stock Market.

The NusaTrip update, filed on Form 8-K with the Securities and Exchange Commission on February 3, 2026, outlines a sequence of communications with Nasdaq and the SEC. It states that following NusaTrip's initial response on October 14, 2025 to an October 9, 2025 information request from Nasdaq, the exchange sought additional information through follow-up requests.

According to the filing, NusaTrip supplied written answers to those follow-up requests on November 17, 2025. The company reports it received a request from the SEC on December 22, 2025 for the voluntary production of documents, to which it provided responses on January 20, 2026.

As of the latest update, trading in NusaTrip's securities remains halted on Nasdaq. NusaTrip stated it is cooperating fully with both the SEC and Nasdaq to address any outstanding matters and indicated it will issue further updates as appropriate.

The filing also notes that NusaTrip's day-to-day business activities continue to operate normally and have not been materially affected by the trading suspension. Society Pass is described in the filing as a Southeast Asia e-commerce ecosystem, while NusaTrip is identified as an integrated travel technology platform operating in Southeast Asia and the broader Asia-Pacific region.

The market reaction to the regulatory disclosure was immediate for Society Pass, with the share price retreating in response to the ongoing suspension of its affiliate's securities. The regulatory timeline provided in NusaTrip's 8-K traces the exchange and SEC interactions through multiple written submissions but does not specify a timeline for lifting the trading halt.


Investors and market observers will likely monitor subsequent filings and statements from NusaTrip, Nasdaq and the SEC for indications of any change in the trading status. For now, the company emphasizes cooperation with regulators and asserts its operations remain uninterrupted.

Risks

  • Ongoing regulatory inquiries and the continued Nasdaq trading suspension for NusaTrip create uncertainty for shareholders - this affects equity liquidity and market assessment of the companies.
  • No timeline was provided for resolving outstanding matters with Nasdaq and the SEC, leaving potential for prolonged suspension or additional regulatory actions - impacting investor confidence in related travel and e-commerce stocks.

More from Stock Markets

Puig and Estée Lauder Families Discuss Share-Structure Moves to Narrow Ownership Gap Mar 26, 2026 GAM trims 2025 losses through cost cuts but says profit recovery will be slower Mar 26, 2026 RBC Re-weights Southern European Utilities: Downgrades REN and Terna, Elevates Italgas Mar 26, 2026 Wacker Neuson Posts Higher EBIT Despite Slight Revenue Slip in 2025 Mar 26, 2026 Innate Pharma sees revenue plunge, signals cash runway to Q3 2026 as trials await financing Mar 26, 2026